Logo image of OYST

OYSTER POINT PHARMA INC (OYST) Stock Fundamental Analysis

NASDAQ:OYST - Nasdaq - US69242L1061 - Common Stock - Currency: USD

11.17  +0.02 (+0.18%)

After market: 11.17 0 (0%)

Fundamental Rating

1

Taking everything into account, OYST scores 1 out of 10 in our fundamental rating. OYST was compared to 571 industry peers in the Biotechnology industry. OYST may be in some trouble as it scores bad on both profitability and health. OYST does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OYST has reported negative net income.
OYST had a negative operating cash flow in the past year.
OYST Yearly Net Income VS EBIT VS OCF VS FCFOYST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 -20M -40M -60M -80M -100M

1.2 Ratios

The profitability ratios for OYST are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OYST Yearly ROA, ROE, ROICOYST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OYST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OYST Yearly Profit, Operating, Gross MarginsOYST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 0 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

OYST does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OYST has more shares outstanding
Compared to 1 year ago, OYST has a worse debt to assets ratio.
OYST Yearly Shares OutstandingOYST Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M
OYST Yearly Total Debt VS Total AssetsOYST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -7.49, we must say that OYST is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -7.49, OYST is not doing good in the industry: 76.71% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.49
ROIC/WACCN/A
WACC9.28%
OYST Yearly LT Debt VS Equity VS FCFOYST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 0 50M -50M 100M 150M

2.3 Liquidity

OYST has a Current Ratio of 3.35. This indicates that OYST is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.35, OYST is doing worse than 69.57% of the companies in the same industry.
OYST has a Quick Ratio of 3.11. This indicates that OYST is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.11, OYST is doing worse than 70.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.35
Quick Ratio 3.11
OYST Yearly Current Assets VS Current LiabilitesOYST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for OYST have decreased strongly by -113.14% in the last year.
OYST shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.15%.
EPS 1Y (TTM)-113.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-101.47%
Revenue 1Y (TTM)9.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-68.84%

3.2 Future

Based on estimates for the next years, OYST will show a decrease in Earnings Per Share. The EPS will decrease by -0.70% on average per year.
The Revenue is expected to grow by 105.78% on average over the next years. This is a very strong growth
EPS Next Y-66.47%
EPS Next 2Y4.31%
EPS Next 3Y14.43%
EPS Next 5Y-0.7%
Revenue Next Year55.43%
Revenue Next 2Y130.27%
Revenue Next 3Y117.27%
Revenue Next 5Y105.78%

3.3 Evolution

OYST Yearly Revenue VS EstimatesOYST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M
OYST Yearly EPS VS EstimatesOYST Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OYST. In the last year negative earnings were reported.
Also next year OYST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OYST Price Earnings VS Forward Price EarningsOYST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OYST Per share dataOYST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as OYST's earnings are expected to grow with 14.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.31%
EPS Next 3Y14.43%

More info and screens

0

5. Dividend

5.1 Amount

OYST does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OYSTER POINT PHARMA INC

NASDAQ:OYST (12/30/2022, 8:00:02 PM)

After market: 11.17 0 (0%)

11.17

+0.02 (+0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2022-11-10/amc
Earnings (Next)02-22 2023-02-22
Inst Owners0%
Inst Owner Change0%
Ins Owners31.31%
Ins Owner Change0%
Market Cap299.85M
Analysts78
Price Target28.05 (151.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.77%
Min EPS beat(2)-10.44%
Max EPS beat(2)11.98%
EPS beat(4)1
Avg EPS beat(4)-3.32%
Min EPS beat(4)-13.56%
Max EPS beat(4)11.98%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-13.2%
Min Revenue beat(2)-20.89%
Max Revenue beat(2)-5.52%
Revenue beat(4)2
Avg Revenue beat(4)518.44%
Min Revenue beat(4)-20.89%
Max Revenue beat(4)2055.56%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.77%
PT rev (3m)N/A
EPS NQ rev (1m)0.9%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.16%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-8.11%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.96%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.31
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.65
EYN/A
EPS(NY)-3.53
Fwd EYN/A
FCF(TTM)-6.2
FCFYN/A
OCF(TTM)-6.18
OCFYN/A
SpS0.73
BVpS-0.83
TBVpS-0.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 140.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.35
Quick Ratio 3.11
Altman-Z -7.49
F-Score2
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)976.06%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-113.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-101.47%
EPS Next Y-66.47%
EPS Next 2Y4.31%
EPS Next 3Y14.43%
EPS Next 5Y-0.7%
Revenue 1Y (TTM)9.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-68.84%
Revenue Next Year55.43%
Revenue Next 2Y130.27%
Revenue Next 3Y117.27%
Revenue Next 5Y105.78%
EBIT growth 1Y-98.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.36%
EBIT Next 3Y-9.7%
EBIT Next 5Y-2.78%
FCF growth 1Y-206.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-208%
OCF growth 3YN/A
OCF growth 5YN/A